aspirin + clopidogrel + atorvastatin

Aspirin + clopidogrel + atorvastatin is a triple therapy combination of three distinct pharmaceutical agents: aspirin, clopidogrel, and atorvastatin. This combination is primarily used for the prevention of cardiovascular events such as heart attacks and strokes, particularly in patients with existing cardiovascular disease or those at high risk, including individuals who have undergone coronary artery stenting or experienced a previous heart attack or stroke. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), exerts its effects by irreversibly inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins and thromboxanes, leading to anti-inflammatory, analgesic, antipyretic, and antiplatelet actions. Clopidogrel is a prodrug that, upon metabolism, irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. Atorvastatin, a statin, functions as a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, which reduces cholesterol production in the liver and increases hepatic LDL receptors, ultimately lowering LDL-C levels and also affecting triglycerides and HDL-C. The synergistic action of these three drugs addresses multiple risk factors, including platelet aggregation, inflammation, and high cholesterol, to provide comprehensive cardiovascular protection.

Brand names

ATOVASTRIN GOLD

Other names

aspirin + atorvastatin + clopidogrel